Urogen Pharma Stock Price, News & Analysis

UroGen Pharma Ltd. (Nasdaq: URGN) will participate in a fireside chat at the H.C. Wainwright BioConnect Conference on May 2, 2023 from 10:00 AM ET. This event aims to showcase UroGen's dedication to developing innovative treatments for urothelial and specialty cancers.

A live audio webcast will be accessible via the company's investor website, with a replay available for approximately 30 days post-event.

UroGen specializes in proprietary technologies, notably RTGel®, a sustained-release hydrogel platform that enhances drug efficacy in treating urinary tract conditions. Its products, including Jelmyto® and investigational UGN-102, aim to non-surgically ablate tumors. UroGen is based in Princeton, NJ, and operates in Israel.

UroGen Pharma Ltd. reported full-year 2022 net product revenues of $64.4 million, a 34% increase from 2021. The company completed patient enrollment in the ENVISION Phase 3 trial for UGN-102 targeting low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Topline data from pivotal studies is expected mid-2023, with an NDA submission anticipated in 2024. UroGen aims for 2023 JELMYTO revenues between $76 million and $86 million. However, the company reported a net loss of $109.2 million for 2022. As of year-end, cash and equivalents totaled approximately $100 million.

UroGen Pharma Ltd. (NASDAQ: URGN) will report its fourth quarter and full-year 2022 financial results on March 16, 2023, before the stock market opens. A conference call will follow at 10:00 AM ET, accessible via a live webcast on UroGen’s Investor Relations website. The company is focused on innovative treatments for urothelial and specialty cancers, featuring its proprietary RTGel™ hydrogel technology and products like Jelmyto® for non-surgical tumor ablation. UroGen aims to improve therapeutic options for patients through sustained release mechanisms.

UroGen Pharma Ltd. (Nasdaq: URGN) recently granted inducement restricted stock units (RSUs) to 7 new employees from March 1 to March 6, 2023, aimed at bolstering its workforce for the commercial launch of Jelmyto® and ongoing pipeline development. A total of 11,700 shares of common stock will be issued upon RSU vesting over three years, contingent on continued employment. The RSUs align with UroGen’s 2019 Inducement Plan and Nasdaq listing Rule 5635(c)(4). UroGen focuses on innovative treatments for urothelial and specialty cancers, with its first commercial product being Jelmyto®.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech firm focused on innovative urothelial cancer treatments, is set to present at two investor conferences in March 2023. The Cowen 43rd Annual Health Care Conference will feature a panel presentation on March 7 from 12:50-1:50pm ET. The Oppenheimer 33rd Annual Healthcare Conference will include a presentation on March 14 from 10:40-11:10am ET. Webcasts for both events will be accessible on UroGen's website, with replays available for 30 days. UroGen's products include JELMYTO and investigational treatment UGN-102.

UroGen Pharma Ltd. (Nasdaq: URGN) has announced promising initial results from a study on UGN-102, an investigational treatment for low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). In a feasibility study, 75% of patients (6 of 8) achieved a complete response three months post-treatment. The study indicates the potential for at-home administration of UGN-102, which may alleviate patient burdens associated with frequent clinical visits. The favorable outcomes support UroGen’s ongoing Phase 3 ENVISION trial for UGN-102, with plans to submit a New Drug Application in 2024, potentially transforming treatment options for bladder cancer patients.